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Background: B cell malignancies are characterized by clonal expansion of B cells expressing tumor-specific
idiotypes on their surface. These idiotypes are ideal target antigens for an individualized immunotherapy. However,
previous idiotype vaccines mostly lacked efficiency due to a low immunogenicity of the idiotype. The objective of
the present study was the determination of the feasibility, safety and immunogenicity of a novel chemically linked
phage idiotype vaccine.
Methods: In the murine B cell lymphoma 1 model, tumor idiotypes were chemically linked to phage particles used
as immunological carriers. For comparison, the idiotype was genetically expressed on the major phage coat protein
g8 or linked to keyhole limpet hemocynanin. After intradermal immunizations with idiotype vaccines, tolerability
and humoral immune responses were assessed.
Results: Feasibility and tolerability of the chemically linked phage idiotype vaccine was demonstrated. Vaccination
with B cell lymphoma 1 idiotype expressing phage resulted in a significant survival benefit in the murine B cell
lymphoma 1 protection model (60.2 ± 23.8 days vs. 41.8 ± 1.6 days and 39.8 ± 3.8 days after vaccination with wild
type phage or phosphate buffered saline, respectively). Superior immunogenicity of the chemically linked phage
idiotype vaccine compared to the genetically engineered phage idiotype and keyhole limpet hemocynanin-
coupled idiotype vaccine was demonstrated by significantly higher B cell lymphoma 1 idiotype-specific IgG levels
after vaccination with chemically linked phage idiotype.
Conclusion: We present a novel, simple, time- and cost-efficient phage idiotype vaccination strategy, which
represents a safe and feasible therapy and may produce a superior immune response compared to previously
employed idiotype vaccination strategies.
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Anti-tumor vaccines hold out the prospect of effective
tumor therapies with minimal side effects. A successful
example is the anti-CD20 antibody rituximab acting as
passive vaccination against B cell lymphoma. However, ri-
tuximab targets CD20 in general, thus depleting not only
B cell lymphoma cells but also normal B cells [1]. It is
envisioned that a personalized active vaccination strategy
targeting tumor-specific antigens may evoke an even* Correspondence: fuat.oduncu@med.uni-muenchen.de
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reproduction in any medium, provided the orbetter and more sustained therapeutic response. An ideal
and easily identifiable tumor-specific antigen is the vari-
able region of the clonal immunoglobulin (idiotype, Id)
expressed on the surface of B cell malignancies, being
unique to each neoplastic B cell clone.
The effectiveness of Id vaccines largely depends on a
sufficient immunogenicity of the Id, which represents a
tumor-specific antigen [2], but nevertheless is a self-
protein. For the purpose of provoking immunogenicity, the
Id is usually coupled to a strong immunogenic carrier pro-
tein, such as keyhole limpet hemocyanin (KLH), and co-
administered with immunostimulatory adjuvants, mainly
granulocyte-monocyte colony stimulating factor (GM-CSF)
[3,4]. Despite these procedures, Id-based immunotherapytral Ltd. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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comes and clinical phase III studies aimed at obtaining
regulatory approval for Id-KLH vaccines failed to reach
their primary endpoints [5,6]. With the aim of enhancing
the idiotype immunogenicity, we utilized the immunogenic
properties of the filamentous phage, which is more typically
employed in phage display technology as a powerful mo-
lecular tool for antibody engineering [7]. Peptides displayed
on the surface of filamentous phage are able to induce
humoral as well as cell-mediated immune responses [8],
making phage particles an attractive antigen delivery system
[9]. We here present a novel chemically linked phage Id
vaccine characterized by a higher Id density on the phage




The hybridoma cell line 123 F6 was used as source for
mouse anti-BCL1 IgM (LGC Standards). Cells were kept
in complete Dulbecco’s Modified Eagle Medium with 10%
(v/v) fetal calf serum, 104 IU/ml Penicillin and 10 mg/ml
Streptomycin (Gibco) at 37°C and 5% CO2. Mouse BCL1-
IgM was purified from the supernatant employing protein
A chromatography followed by ion exchange chromatog-
raphy on an ÄKTA Purifier 10 using Unicorn 4.11 soft-
ware (Amersham Biosciences) with modifications in
accordance with Reichart et al. [10]. Samples (500 μl) were
passed through 0.8 μm and 0.2 μm nitrocellulose filters
and equilibrated with 500 μl 20 mM tetra-sodium diphos-
phate buffer (pH 6.4; Merck, Darmstadt, Germany) at
room temperature for 10 minutes and then bound to a
HiTrap Protein A HP/5 ml column (Amersham Biosci-
ences) equilibrated with binding buffer (100 mM sodium
citrate/150 mM NaCl/pH 6.4; Merck). After removal of
impurities with binding buffer, IgM fractions were eluted
using a pH step gradient (100 mM sodium citrate/
150 mM NaCl/pH 3.5). Samples were collected in tubes
containing 100 μl 1 M Tris/HCl/pH 9.5. The collected
IgM pool was dialyzed against 20 mM Tris/HCl/pH 8.5
and bound to HiTrap Q-HP/5 ml column (Amersham
Biosciences) equilibrated with 20 mM Tris/HCl/pH 8.5.
Samples were eluted with 20 mM Tris/1 M NaCl/pH 8.5
using a linear salt gradient and the paraprotein was dia-
lyzed against phosphate-buffered saline (PBS; Invitrogen,
Karlsruhe, Germany). The purified protein was sterile fil-
tered through a 0.2 μm nitrocellulose; protein concentra-
tion was determined by spectrophotometry at 280 nm.
Preparation of Id vaccines
The preparation of bacteriophages (M13K07, Amersham
Biosciences) at large scale was performed according to
standard methods [11]. For harvesting bacteriophages, the
cell suspension was subjected to centrifugation (15 minutes,4°C, 7,000 rpm). The supernatant was transferred to 1/5
volume of 5 × PEG/NaCl solution (20% (w/v) PEG 6,000/
2.5 M NaCl in water) and incubated at 4°C for 2 h to pre-
cipitate bacteriophages. After centrifugation (15 minutes,
4°C, 7,000 rpm), the resulting pellet was suspended in PBS
and centrifuged again (15 minutes, 4°C, 10,000 rpm). The
resulting supernatant was repeatedly precipitated with
PEG/NaCl solution.
Contaminating endotoxins were removed by repeated
two-phase Triton X-114 separation as described previously
[12], resulting in a reduction of endotoxins to a concentra-
tion of < 1 endotoxin unit/ml as determined by the Limulus
Amebocyte Lysate QCL-1000 Assay. The purified bacterio-
phages were passed through a 0.4 μm nitrocellulose filter.
Recombinant Id-phage carrying the murine BCL1 Id
protein was produced by phagemid rescue employing
M13 helper phage (M13K07, Amersham Biosciences). The
single-chain variable fragment-BCL1 [13] was fused to the
g8 protein of the M13 phage particle bearing a His tag at
the carboxy-terminus. Subsequently, a phage designated
BCL1-g8 was generated and purified employing the tech-
nologies of Apalexo Biotechnology as described [14].
Chemically linked Id-phage designated BCL1-WT was
generated by coupling purified BCL1 to bacteriophages.
500 μl of a 0.1% (v/v) glutaraldehyde/water solution was
added drop wise to 1.5 ml bacteriophage solution
(50 mg/ml in PBS) during slow vortexing until an Id
protein/phage ratio of 1:10 (w/w) was achieved. The
resulting mixture was incubated for 1 hour at 25°C with
agitation at 1600 rpm. The reaction was stopped by
adding 100 μl 1 M glycine/PBS (w/v) for 1 hour at 25°C
with agitation at 1600 rpm. Samples were dialyzed
against PBS and passed through a 0.4 μm nitro cellulose
filter. Chemically linked BCL1-KLH was generated ac-
cordingly, resulting in a conjugate with an Id/KLH ratio
of 1:10 (w/w).Mouse vaccinations
Animal experiments were conducted in accordance with
the European Union Laws and Guidelines and were ap-
proved by the local ethics committee (Ethikkomission der
Medizinischen Klinik, Munich University) and govern-
mental authorities (J.-Nr. 211-2531-22/98). Nine week old
BALB/c mice were purchased from Elevage Janvier and
kept under standardized pathogen-free conditions. For
preclinical investigation of phage Id-vaccines, the murine
BCL1 lymphoma model was employed [15].
Firstly, BCL1 tumor cells (LGC Standards) were culti-
vated by injection of 106 BCL1 cells into BALB/c mice in-
traperitoneally. After four weeks, approximately 108 BCL1
tumor cells were harvested from the spleen and were
characterized by flow cytometry and ELISA. Isolated cells
were found to express IgM and lambda light chain,
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light chains was not detected (data not shown).
Secondly, mice were subcutaneously injected with 1010,
1011 or 5 × 1011 bacteriophages or 0.25 mg BCL1-KLH
with or without addition of 20 μg granulocyte-macrophage
colony stimulating factor (GM-CFS; Leukomax®, Novartis)
as indicated. Vaccinations were carried out weekly for four
weeks.
Thirdly, for examination of vaccine efficacy, 105 BCL1
tumor cells were administered intraperitoneally at day 7
following the last immunization. After challenge with
tumor cells, the spleen usually becomes infiltrated with
lymphoma cells leading to splenomegaly and mice typic-
ally develop leukemia and die within 35 days of injection
[13,15,16]. Mice were monitored by triweekly physical
examination including the palpatory determination of the
spleen size. Termination criteria were a spleen index > 3
according to Vitetta [17] and signs of distress.
Enzyme-linked immunosorbent assay (ELISA)
Assay plates with 96 wells (Costar®, ImmunoChemistry
Technologies) were coated with the respective capture
antibodies (100 μl/well) at 4°C over night, blocked with
PBS plus 1% (v/v) bovine serum albumin (Sigma Aldrich)
and washed three times with PBS, 0.1% (v/v) Tween 20
(Sigma Aldrich). Sera were added to the wells in PBS dilu-
tions of 1/200 or 1/1000 as indicated. Subsequently, the
plate was incubated for 1 hour at 37°C and washed three
times with PBS plus 0.1% (v/v) Tween 20 before 100 μl of
a 1/1000 PBS-dilution of HRP-conjugated detection anti-
bodies (goat-anti-mouse IgG/IgG1/IgG2a, goat-anti-rat
IgG or rat-anti-mouse IgM/lambda/kappa, Southern Bio-
tech) were added to each well for two hours at 37°C. After
washing three times with PBS, 0.1% (v/v) Tween 20,
100 μl of 2,2′-Azinobis [3-ethylbenzothiazoline-6-sulfonic
acid]-diammonium salt substrate (Thermo Fisher Scien-
tific) was added for 20 minutes before stopping the reac-
tion with 100 μl of 1% (w/v) sodium dodecyl sulfate in
PBS (Merck). Sample concentrations were determined by
spectrophotometry at 405 nm.
Flow cytometry
Flow cytometry analyses were conducted with a Coulter
Epics XL-MCL flow cytometer (Beckman). Control-
Fluorescein isothiocyanate (−FITC), CD4-FITC, Control-
phycoerythrin (−PE), CD8-PE, CD45-FITC, CD3-PE,
CD4-PE, CD19-PE, kappa-FTC, lambda-FITC and IgG-,
IgG1-, IgG2a-, IgM-FITC were purchased from Beckmann
Coulter and Southern Biotech.
Statistics
Data are shown as means +/− standard deviation. Signifi-
cance was declared for p-values < 0.05 as assessed by Stu-
dent’s T-test and log-rank test for survival of mice.Results
Determination of the optimal phage dosage
To evaluate the effect of phage dosage with regard to
humoral anti-phage responses that might provide guidance
for determining effective vaccination dosing, mice were
vaccinated weekly with 1010, 1011 or 5 × 1011 phage parti-
cles for 4 weeks and anti-phage IgG responses were evalu-
ated at day 28 after the last vaccination. Phage-specific
antibodies were induced in a dose-dependent manner with
significantly higher IgG levels after application of 5 × 1011
compared to 1010 phages (Figure 1A). No differences were
found between 5 × 1011 BCL1-g8 and wild-type phage.
Considering each IgG isotype IgG1 and IgG2a individually
revealed no significant increase in the isotypes after a
higher dose of the BCL1-g8 vaccine (Figure 1B).
Tumor protection conferred by Id-phage vaccines
In order to explore the feasibility of employing bacterio-
phages in a vaccination strategy in the murine BCL1
lymphoma model, we designed recombinant BCL1-phage
vaccines for use as a potential therapeutic agent. BALB/c
mice (n = 12/group) were vaccinated weekly with 5 × 1011
BCL1-expressing or wild-type bacteriophages (BCL1-g8,
wild-type phage) or PBS. Seven days after the last vaccin-
ation, 105 BCL1 lymphoma cells were injected intraperito-
neally. Survival of mice vaccinated with BCL1-expressing
phage was significantly longer (60.2 ± 23.8 days) compared
to mice vaccinated with wild-type bacteriophages serving as
a control (41.8 ± 1.6 days) or PBS (39.8 ± 3.8 days) (Figure 2;
p < 0.05). All animals in the control treatment groups were
deceased by day 45, while 50% of the BCL1-g8 vaccinated
animals were still surviving. A complete tumor protection
(survival without any clinical sign of tumor growth until
the end of the 100 day observation period) was observed in
25% of the BCL-g8 vaccinated mice.
Humoral immune response after vaccination of mice
Anti-phage humoral immune response
We next examined the immunogenic properties of the
phage vaccine with respect to humoral immunity. The in-
duction of phage-specific IgG was compared for wild-type
phages, recombinant BCL1-expressing phages (BCL1-g8)
and wild-type phages chemically coupled to the BCL1 pro-
tein (BCL1-WT). As shown in Figure 3A, mice vaccinated
with either wild-type phage or BCL1-g8 and BCL1-WT re-
vealed similar anti-phage IgG levels with small inter-
individual variations and a trend towards lower IgG levels
after vaccination with BCL1-WT compared to wild type
phage.
To determine the sustainability of the anti-phage
humoral response, total IgG levels were determined at day
14, 28 and 4 months (day 120) after the last of 4 weekly
vaccinations. Figure 3B shows the time course of the total
anti-phage IgG response. All phage vaccinations induced
Figure 1 Determination of the phage vaccine dosage. The humoral immune response after vaccination of mice with phage was determined
by ELISA (antibody dilution: 1/1000). (A) Total IgG response at day 28 was measured after the last vaccination with 1010, 1011 or 5 × 1011 phage
particles weekly for 4 weeks (n = 6). (B) Anti-phage specific IgG isotype levels before and at day 28 after 4 weekly vaccinations with 1010, 1011 or
5 × 1011 phage particles (n = 6). * p > 0.05.
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points. Notably, the phage-specific IgG response was sig-
nificantly weaker at day 14 in the BCL1-WT group as
compared to the BCL1-g8 group. However, at day 28 and
120, anti-phage IgG levels were similar for both groups.
With regard to the induction of anti-phage IgG isotype
levels, a similar pattern with lower IgG1 and IgG2a levels
was observed in the BCL1-WT group at day 14 compared
to the BCL1-g8 group, but again, similar levels were
detected in both groups by day 120 (data not shown).
Anti-phage IgG levels were lower for both the BCL1-g8
and BCL1-WT vaccines at day 120 in comparison to wild-
type phage.
There was a non-significant trend towards lower
anti-phage IgM levels with increasing vaccination doseFigure 2 Tumor protection procured by Id-phage vaccines.
Kaplan-Meier plot of the survival of the mice vaccinated weekly with
5 × 1011 bacteriophages (BCL1-g8 or PBS or wild type phage as
control). Seven days after the last vaccination, 105 BCL1 cells were
injected intraperitoneally; n = 12. p < 0.05 (BCL1-g8 vs. wild type
phage and vs. PBS).(Figure 4A). Addition of 20 μg GM-CSF (s.c.) to vacci-
nations with 5 × 1011 BCL1-g8 or wild type phage did
not induce significantly higher total anti-phage IgG,
IgG1 or IgG2a plasma levels (Figure 4B).
Anti-Id humoral immune response
Most importantly for the determination of any potential
benefit in our vaccine’s effects, we next measured anti-Id-
specific humoral responses generated in response to the
phage vaccines. Figure 5A shows the anti-BCL1-specific IgG
responses at day 14, 28 and 120 after vaccination with 5 ×
1011 BCL1-g8 or BCL1-WT phage and in comparison to
BCL1-KLH treatment. Strikingly, BCL1 Id-specific IgG levels
were found to be significantly higher in the BCL1-WTgroup
as compared to the BCL1-KLH and the BCL1-g8 group at
all time points, indicating the superiority of the BCL1-WT
vaccine formulation. Moreover, preliminary data indicates
higher IgG2a anti-Id levels after BCL1-WT compared to
BCL1-KLH vaccination at day 14 and 120 (Figure 5B).
Discussion
The chemically linked phage Id vaccine represents a fast
and cost efficient method for generating tumor-specific vac-
cinations at high yield quantities. In the murine BCL1
lymphoma model, feasibility and tolerability of this phage
Id vaccination strategy was demonstrated. Phage particles
offer an excellent antigen delivery system and a powerful
tool for vaccine design [18], as peptides expressed as re-
combinant fusions with either the minor coat protein g3 or
the major coat protein g8 [19,20] can be easily presented to
the immune system as part of the coat protein. In order to
utilize the powerful phage-inherent immunogenicity for Id
vaccination, we took advantage of the phage’s feature to al-
locate thousands of well-defined sites available for chemical
conjugation [21] and chemically coupled the high molecular
weight BCL1 Id to the phage surface at a high density.
Figure 3 Anti-phage IgG response. The humoral immune response after vaccination of mice with phage was determined by ELISA (antibody
dilution: 1/1000). (A) Total IgG response of single mice 4 weeks (day 28) after the last of 4 weekly vaccinations with PBS, BCL1-KLH, BCL1-g8,
BCL1-WT or wild type phage (n = 6). (B) Sustainability of the humoral immune response to phage vaccines: Anti-phage IgG levels before (day 0)
and at day 14, 28 and 120 after the last of 4 weekly vaccinations with BCL1-g8, BCL1-WT or wild type phage (5 × 1011 each; n = 6). * p > 0.05,
*** p < 0.001.
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revealed a superior immunogenicity of the novel phage
vaccine formulation in comparison to previously used Id
vaccination regimens. Id-specific antibody levels were sig-
nificantly higher and rose earlier after vaccination with the
novel phage vaccine as compared to vaccination with the
BCL1-KLH and the BCL1-g8 vaccine. Thus, although
KLH-coupled Id proteins still represent the gold standard
for Id vaccinations and have been shown to provide pro-
tection in the murine tumor challenge model [22,23],
chemically conjugated Id-phage seems to have the poten-
tial of a superior immune reaction. The observation that
the novel phage Id composition obtained by chemical
coupling induced lower phage-specific IgG responses as
compared to the BCL1-g8 hybrid phage formulation is
possibly due to both a higher Id density and chemical
crosslinking of the BCL1-WT phages, thus covering
phage-specific antigens against B cell recognition.
Besides the induction of Id-specific antibodies, cellular
immune response is also of importance for producing an
effective anti-tumor response. In treatment-naive patients
with indolent B cell lymphoma, only cellular-mediatedFigure 4 Anti-phage IgM response and IgG response with or without
after the last vaccination with 1010, 1011 or 5 × 1011 phage particles weekly
IgG isotype levels at day 28 after 4 weekly vaccinations with 5 × 1011 phag
dilution: 1/1000).responses correlated with superior progression-free sur-
vival and durable objective remissions [24]. In multiple
myeloma patients, the cellular immune response is espe-
cially crucial, since myeloma cells secrete their tumor-
specific immunoglobulins and thus the anti-Id humoral
immune response may result in binding and neutralizing
of anti-Id specific antibodies by soluble paraproteins [25].
Accordingly, reduction of circulating myeloma cells corre-
lates with vaccine-induced Id-specific T cell responses
[26]. In this context, it is fundamental that phages are able
to be incorporated by antigen-presenting cells and to
induce not only a humoral, but also a cellular immune re-
sponse [8,27]. Uptake and processing of the phage-
coupled Id protein and subsequent presentation via both
the MHC I and II is very likely. Antibody subtype analysis
in the phage-vaccinated mice revealed that Id-KLH in-
duced mainly the IgG1 isoform. In contrast, BCL1-WT
vaccination induced a more predominant IgG2a response,
which is considered to be favorable for lymphoma protec-
tion [22,28]. IgG2a is associated with Th1 responses in
mice, which are related to better T cell-mediated immune
response and tumor killing [29]. Furthermore, antibody-addition of GM-CSF. (A) IgM responses at day 28 were measured
for 4 weeks (n = 6; antibody dilution: 1/200). (B) Anti-phage specific
e particles with or without addition of 20 μg GM-CSF (n = 6; antibody
Figure 5 Anti-phage IgG response. The anti-phage humoral immune response after vaccination of mice with phage was determined by ELISA
(antibody dilution: 1/1000) (A) Anti-BCL1-specific IgG response before (day 0) and at day 14, 28 and 120 after vaccination with PBS, wild type
phage, BCL1-KLH, BCL1-g8 or BCL1-WT (5 × 1011 each; n = 6). (B) Anti-BCL1-specific IgG isotypes at day 14 and 120 after vaccination. * p > 0.05,
** p < 0.01; *** p < 0.001.
Roehnisch et al. Journal of Translational Medicine 2013, 11:267 Page 6 of 7
http://www.translational-medicine.com/content/11/1/267mediated cellular cytotoxicity is mainly dependent on
IgG2a [28,30] and IgG2a was shown to yield a better anti-
lymphoma effect [22].
Most Id vaccination studies use GM-CSF as adjuvant
to induce a stronger cellular immune response, presum-
ably by recruitment of dendritic cells [3,4]. However, the
use of GM-CSF in Id-vaccination is controversial, as on
the one hand GM-CSF might be important for inducing
a T cell response to Id vaccination, which is supported
by the fact that GM-CSF in combination with IL-12
leads to a stronger induction of an Id-specific T cell re-
sponse than IL-12 alone in myeloma patients [31,32].
On the other hand, GM-CSF was shown to induce
growth-stimulating effects on human myeloma cells
in vitro [33] and extramedullary progression of multiple
myeloma [34]. In the present study, GM-GSF did not in-
duce a stronger antibody response or a survival benefit
compared to phage Id vaccination alone, suggesting that
the strong immunogenicity of the phage vaccine formu-
lation itself is sufficient to induce an effective immune
response without the use of an additional adjuvant.
Thus, omission of GM-CSF adjuvant may be worth con-
sidering in future studies employing phage vaccine
formulations.
Further strategies to improve the Id immunogenicity are
under investigation. With regard to the role of phage as a
carrier for future vaccine formulations, phage may be fur-
ther optimized by design, for example by co-expression of
fragments or antigenic determinants, which promote the
uptake of bacteriophages by dendritic cells and thus the
tumor-protective capacity [35]. On the other hand, genetic
removal or modification of immunodominant regions of
coat proteins was demonstrated to focus and improve the
epitope-specific immune response by decreasing the anti-
gen complexity of the phage surface [36].
A strength of the current study is the comprehensive
assessment of the humoral immune response against a
novel phage-Id formulation in comparison to the previ-
ously known genetically engineered Id-phage and thegold standard Id-KLH using the established ELISA method.
The major limitation is that we did not directly examine
the cellular immune response. Furthermore, we employed
the murine BCL1 lymphoma model as a model for B cell
malignancies with paraprotein secretion and clinical trials
in myeloma patients are needed to confirm the tolerability
and efficacy of the novel vaccine in humans.
Conclusions
While refinements for increasing the immunogenicity of
the target Id may still be needed, we conclude from our
data that Id proteins chemically conjugated to phage parti-
cles appear to be suitable for use as vaccines. The immune
stimulatory potential of the chemically linked phage Id-
vaccine appears to be superior to the gold standard Id-
KLH vaccine and to genetically engineered phage vaccines.
Based on the encouraging immune responses generated in
the murine BCL1 lymphoma model, we believe that clin-
ical trials including patients with B cell malignancies are
warranted to confirm the therapeutic efficiency of this
approach.
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